Comparative effec- tiveness of revascularization strategies. N Engl J Med. 2012;366:1467 76. 80. Benedetto U, Melina G, Angeloni E, et al. Coronary artery bypass graft- ing versus drug-eluting stents in multivessel coronary disease. A meta- analysis on 24,268 patients. Eur J Cardiothorac Surg. 2009;36:611 5. 81. Morice MC, Serruys PW, Kappetein AP, et al. Outcomes in patients with de novo left main disease treated with either percutaneous coronary inter- vention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial. Circulation. 2010;121:2645 53. 82. Kappetein AP, Feldman TE, Mack MJ, et al. Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. Eur Heart J. 2011;32:2125 34. 83. Kappetein AP, Head SJ, Morice MC, et al. Treatment of complex coro- nary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. Eur J Cardiothorac Surg. 2013;43:1006 13. 84. Ragosta M, Dee S, Sarembock IJ, et al. Prevalence of unfavorable angio- graphic characteristics for percutaneous intervention in patients with unprotected left main coronary artery disease. Catheter Cardiovasc Interv. 2006;68:357 62. 85. Deleted in press. 86. Mohr FW, Morice MC, Kappetein AP, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three- vessel disease and left main coronary disease: 5-year follow-up of the ran- domised, clinical SYNTAX trial. Lancet. 2013;381:629 38. 87. Buszman PE, Kiesz SR, Bochenek A, et al. Acute and late outcomes of unprotected left main stenting in comparison with surgical revasculariza- tion. J Am Coll Cardiol. 2008;51:538 45. 88. Park SJ, Kim YH, Park DW, et al. 